Azoles

George R. Thompson, Thomas F Patterson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

Original languageEnglish (US)
Title of host publicationAspergillosis: From Diagnosis to Prevention
PublisherSpringer Netherlands
Pages231-262
Number of pages32
ISBN (Print)9789048124084, 9789048124077
DOIs
StatePublished - 2010

Fingerprint

Azoles
Triazoles
Itraconazole
Aspergillosis
Polyenes
Amphotericin B
Therapeutics
Pharmacokinetics
posaconazole
Voriconazole

Keywords

  • Albaconazole
  • Isavuconazole
  • Itraconazole
  • Posaconazole
  • Ravuconazole
  • Triazoles
  • Voriconazole

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thompson, G. R., & Patterson, T. F. (2010). Azoles. In Aspergillosis: From Diagnosis to Prevention (pp. 231-262). Springer Netherlands. https://doi.org/10.1007/978-90-481-2408-4_15

Azoles. / Thompson, George R.; Patterson, Thomas F.

Aspergillosis: From Diagnosis to Prevention. Springer Netherlands, 2010. p. 231-262.

Research output: Chapter in Book/Report/Conference proceedingChapter

Thompson, GR & Patterson, TF 2010, Azoles. in Aspergillosis: From Diagnosis to Prevention. Springer Netherlands, pp. 231-262. https://doi.org/10.1007/978-90-481-2408-4_15
Thompson GR, Patterson TF. Azoles. In Aspergillosis: From Diagnosis to Prevention. Springer Netherlands. 2010. p. 231-262 https://doi.org/10.1007/978-90-481-2408-4_15
Thompson, George R. ; Patterson, Thomas F. / Azoles. Aspergillosis: From Diagnosis to Prevention. Springer Netherlands, 2010. pp. 231-262
@inbook{b47fc9abe9e846a09bf9448ee9a46829,
title = "Azoles",
abstract = "The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.",
keywords = "Albaconazole, Isavuconazole, Itraconazole, Posaconazole, Ravuconazole, Triazoles, Voriconazole",
author = "Thompson, {George R.} and Patterson, {Thomas F}",
year = "2010",
doi = "10.1007/978-90-481-2408-4_15",
language = "English (US)",
isbn = "9789048124084",
pages = "231--262",
booktitle = "Aspergillosis: From Diagnosis to Prevention",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Azoles

AU - Thompson, George R.

AU - Patterson, Thomas F

PY - 2010

Y1 - 2010

N2 - The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

AB - The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

KW - Albaconazole

KW - Isavuconazole

KW - Itraconazole

KW - Posaconazole

KW - Ravuconazole

KW - Triazoles

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84919687646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919687646&partnerID=8YFLogxK

U2 - 10.1007/978-90-481-2408-4_15

DO - 10.1007/978-90-481-2408-4_15

M3 - Chapter

AN - SCOPUS:84919687646

SN - 9789048124084

SN - 9789048124077

SP - 231

EP - 262

BT - Aspergillosis: From Diagnosis to Prevention

PB - Springer Netherlands

ER -